MAPT and Alzheimer disease: The key aspects of this assay that distinguish it from other reported cellular assays of tau aggregate formation are (1) the utilization of primary neurons, (2) the absence of human tau transgene expression, and (3) the initiation of tau inclusion formation through seeding of the neuron cultures with pathologic tau enriched from human AD brains (AD-tau) (28).